非酒精性脂肪性肝病相关肝细胞癌的发病机制及FXR和OCA的研究进展

摘要

非酒精性脂肪性肝病(non-alcoholic fatty liver disease,NAFLD)进展为肝细胞癌(hepatocellular carcinoma,HCC)的发病机制是相当复杂的,其中涉及多个方面,包括高胰岛素环境、细胞学机制、遗传多态性等.为预防NAFLD进展为HCC,干预和治疗NAFLD是必然的选择.法尼醇X受体(Farnesoid X receptor,FXR)的活化可以改善NAFLD的组织学特征.作为FXR激动剂奥贝胆酸(Obeticholicacid,OCA)又名6-乙基鹅去氧胆酸,是目前一种治疗NAFLD的新药物.本文就NAFLD相关HCC发病机制、FXR和OCA的研究进展作一概述.%The pathogenesis of non-alcoholic fatty liver disease (NAFLD) progress to hepatocellular carcinoma (HCC) is quite complex,which involves many aspects,including the high insulin environment,cytological mechanisms,genetic polymorphism and so on.In order to prevent the development of NAFLD as HCC,intervention and treatment of NAFLD are inevitable choice.The Farnesoid X receptor (FXR) activation can improve the histological features of NAFLD.As an FXR agonist,Obeticholic acid (OCA,6-ethylchenodeoxycholic acid) is a new drug for the treatment of NAFLD currently.In this article,the pathogenesis of NAFLD-related HCC,FXR and OCA research progress were introduced.